Therapeutic Solutions International Prevention Subsidiary Campbell Neurosciences Receives Notice of Allowance on Suicide Prevention Drug Candidate

Therapeutic Solutions International, Inc. (TSOI), announced today issuance of a Notice of Allowance from the United States Patent and Trademark Office on its patent application covering a novel composition of matter being developed for prevention of suicide.

Campbell Neuroscience has been focusing on creating a diagnostic based approach on identifying patients at risk of suicide using immunology-based assays, which was the basis for the Campbell Score, which was validated by a previous clinical trial¹.

“Our findings, as well as those of independent researchers, strongly suggest a specific type of neuroinflammation contributes to suicidal thoughts and actions. This is further supported by studies showing drugs whose side effects are to increase this “brain inflammation” trigger suicidal thoughts in patients. Importantly, these thoughts of self-harm cease when the drugs are discontinued,” said Thomas Ichim, Ph.D., President, and Chief Scientific Officer of Campbell Neurosciences. “The granting of a patent on our novel approach to reduce this specific type of brain inflammation is a landmark event for our Company as we work tirelessly for a world without suicide.”

“Having worked on the development of the Company’s novel approach, I am confident in our ability to rapidly conduct clinical trials and achieve market entry,” said Dr. James Veltmeyer, Chief Medical Officer of the Company. “There is a great need for suicide preventing approaches that are not classical antidepressants. Our approach is distinctly different based on its targeting of neuroinflammation and pathologically altered immunity in the brain.”

Campbell Neurosciences created numerous products in the diagnosis of suicidal tendencies as well as suppression of inflammatory events in the brain, some of which are described in the following press release².

“The speed at which Campbell Neurosciences is moving in meeting its milestones is truly inspiring,” stated Timothy Dixon, President, and CEO of Therapeutic Solutions International and Chairman of Campbell Neurosciences. “I commend Dr. Ichim for leveraging his immunological and corporate expertise in not only advancing our science, but also recruiting internationally renowned leaders from the business and medical world to join us in the fight against this terrible pandemic of suicide.”

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

1 Therapeutic Solutions International Spin-Off Campbell Neurosciences Announces Positive Clinical Trial Results for Campbell Score Blood Based Suicide Prediction (prnewswire.com)

2 Therapeutic Solutions International Spin-Off Campbell Neurosciences Provides Progress Update in Quest for Addressing Suicide as a Medical Condition | Business Wire

View source version on businesswire.com: https://www.businesswire.com/news/home/20230731364539/en/